AML Risk Stratification Gene Panel

The AML risk stratification gene panel by Next-Generation Sequencing (NGS) is a groundbreaking tool in the field of acute myeloid leukemia (AML) diagnosis and treatment. This gene panel utilizes the power of NGS technology to analyze a comprehensive set of genes associated with AML, enabling a more accurate and detailed assessment of a patient's risk profile. By examining specific genetic mutations and alterations, the panel allows for precise identification of high-risk AML patients who may require more aggressive treatment strategies. It also helps in predicting treatment response and relapse likelihood, aiding in personalized therapeutic approaches.

Note: Genetic counseling can be provided. If interested, please send the request to this email id:[email protected]

.